본문 바로가기

Effect of Combination Therapy with Ezetimibe and Statins versus Statin Monotherapy on Carotid Intima-Media Thickness: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q3Scopus Q2
저널
MEDICINA-LITHUANIA59(11) · 2023
피인용
Web of Science 4Scopus 5
FWCI (Scopus)
0.64
JCR IF
JCR 2022 2.6
ISSN
1010-660X

저자

  1. 권력준제1저자Pusan Natl Univ, Yangsan Hosp, Family Med Clin, Yangsan 50612, South Korea
  2. 조영혜Pusan Natl Univ, Sch Med, Dept Family Med, Yangsan 50612, South Korea
  3. 박은주Pusan Natl Univ, Yangsan Hosp, Family Med Clin, Yangsan 50612, South Korea
  4. 이영인Pusan Natl Univ, Yangsan Hosp, Family Med Clin, Yangsan 50612, South Korea
  5. 이새롬Pusan Natl Univ, Yangsan Hosp, Family Med Clin, Yangsan 50612, South Korea
  6. 최정인Pusan Natl Univ, Yangsan Hosp, Family Med Clin, Yangsan 50612, South Korea
  7. 이상엽Pusan Natl Univ, Yangsan Hosp, Family Med Clin, Yangsan 50612, South Korea
  8. 손수민교신저자Pusan Natl Univ, Yangsan Hosp, Family Med Clin, Yangsan 50612, South Korea

초록

Background and Objectives: Lipid-lowering agents such as ezetimibe are recommended in uncontrolled hyperlipidemia for primary and secondary prevention of cardiovascular disease. Carotid intima-media thickness (CIMT) is a surrogate marker of atherosclerosis and a predictor of cardiovascular and cerebral events. The effects of ezetimibe on CIMT have been inconsistently reported. The aim of this meta-analysis is to compare the effects of ezetimibe/statin and statin alone therapies on CIMT reduction. Materials and Methods: The PubMed, Embase, and Cochrane library databases were searched for randomized controlled trials (RCTs) published prior to 26 January 2023 with the MeSH keywords 'Ezetimibe' and 'Carotid Intima-Media Thickness'. The results were presented as standard mean difference (SMD) with 95% confidence intervals using the random-effect model method, and heterogeneity was assessed. Subgroup, meta-regression, and sensitivity analyses were conducted. Results: Five RCTs with 642 participants were included. CIMT reduction was not significantly different between the ezetimibe/statin and statin alone groups. However, in subgroup analyses, CIMT in the ezetimibe/statin group was significantly reduced in patients with non-familial hypercholesterolemia (SMD: -0.34 mm and p = 0.002) and in patients with secondary prevention (SMD: -0.38 mm and p = 0.002). The low-density lipoprotein cholesterol level was significantly reduced in the ezetimibe/statin group (SMD: -0.58 mg/dL and p < 0.001). Conclusions: The effect of ezetimibe on CIMT reduction was shown in non-familial hypercholesterolemia and secondary prevention. These results suggest that the efficacy of ezetimibe may vary with potential CIMT reduction benefits in certain subpopulations.

키워드

atherosclerosiscardiovascular diseaseezetimibeintima-media thicknessstrokeCARDIOVASCULAR RISKADDING EZETIMIBEATHEROSCLEROSISATORVASTATINSTROKEPLAQUEEFFICACYSAFETY

식별자

Scopus EID
2-s2.0-85177751964
WoS UID
001114539800001